Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of “Hold” from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been given an average rating of “Hold” by the seven research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $29.40.

Several research firms have weighed in on PCRX. Barclays cut their target price on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Royal Bank Of Canada raised their price target on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research report on Friday, May 1st. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Weiss Ratings raised Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Finally, Zacks Research raised Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th.

Insider Transactions at Pacira BioSciences

In other news, CFO Shawn Cross sold 12,941 shares of the firm’s stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total transaction of $325,595.56. Following the sale, the chief financial officer owned 105,341 shares of the company’s stock, valued at $2,650,379.56. This trade represents a 10.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jonathan Slonin sold 3,261 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the sale, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. This represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 28,261 shares of company stock worth $702,610. 6.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of Pacira BioSciences by 175.4% during the third quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after buying an additional 721 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Pacira BioSciences by 5,900.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after buying an additional 1,475 shares in the last quarter. Meeder Asset Management Inc. bought a new position in shares of Pacira BioSciences during the first quarter worth about $46,000. Kestra Advisory Services LLC acquired a new stake in Pacira BioSciences in the 4th quarter valued at $48,000. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Pacira BioSciences during the 4th quarter worth about $51,000. 99.73% of the stock is currently owned by institutional investors.

Pacira BioSciences Trading Down 3.1%

NASDAQ:PCRX opened at $22.25 on Wednesday. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $27.64. The business’s 50-day moving average price is $23.59 and its two-hundred day moving average price is $23.32. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $875.54 million, a price-to-earnings ratio of 185.43 and a beta of 0.29.

Pacira BioSciences (NASDAQ:PCRX) last released its earnings results on Thursday, April 30th. The company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The company had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. During the same period in the previous year, the company posted $0.65 EPS. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities analysts expect that Pacira BioSciences will post 1.91 earnings per share for the current year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.